JNJ

3 Best Big Pharma Stocks for 2018
3 Best Big Pharma Stocks for 2018
Motley Fool
JNJ
Celgene
AbbVie
Flag link:
Biotech sector ensures highest premium among M&A transactions
Biotech sector ensures highest premium among M&A transactions
GoinPharma
biotech
M&A
Kite Pharma
Gilead Sciences
JNJ
Actelion
Flag link:
J&J’s big blockbuster hopeful esketamine scores high for major depression — but side effects haunt results
J&J’s big blockbuster hopeful esketamine scores high for major depression — but side effects haunt results
Endpoints
JNJ
esketamine
major depression
Flag link:
Celgene shares sink after another PhIII lymphoma flop and J&J steps up for the late-stage BCMA race
Celgene shares sink after another PhIII lymphoma flop and J&J steps up for the late-stage BCMA race
Endpoints
Celgene
JNJ
clinical trials
Revlimid
follicular lymphoma
Flag link:
J&J wows with a $350M cash deal to partner on CAR-T with Legend, a one-time unknown until its star turn at ASCO
J&J wows with a $350M cash deal to partner on CAR-T with Legend, a one-time unknown until its star turn at ASCO
Endpoints
JNJ
CAR-T
Legend Biotech
LCAR-B38M
BCMA
China
Flag link:
Johnson & Johnson unit sues ex-rep over defection to Zimmer Biomet
Johnson & Johnson unit sues ex-rep over defection to Zimmer Biomet
Mass Device
JNJ
device reps
sales poaching
Zimmer Biomet
devices
Flag link:
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
Endpoints
drug launches
Bictegravir/F/TAF
Gilead Sciences
semaglutide
Novo Nordisk
epacadostat
Incyte
Rova-T
AbbVie
ozanimod
Celgene
apalutamide
JNJ
Elagolix
AVXS-101
AveXis
lanadelumab
Shire
Epidiolex
GW Pharma
Flag link:
[video]ASH 2017 Recap: These Were the Big Winners and Losers
[video]ASH 2017 Recap: These Were the Big Winners and Losers
Motley Fool
ASH2017
Bluebird Bio
Juno Therapeutics
Spark Therapeutics
Biomarin
JNJ
Celgene
Flag link:
Pfizer Not Planning US Launch of its Second Remicade Biosimilar Approved by FDA
Pfizer Not Planning US Launch of its Second Remicade Biosimilar Approved by FDA
RAPS.org
Pfizer
biosimilars
Remicade
Ixifi
Inflectra
JNJ
Flag link:
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Yahoo/Reuters
Pfizer
biosimilars
JNJ
Remicade
Ifixi
rheumatoid arthritis
Crohn's Disease
Flag link:
Janssen Oncology rolls out Cancer.com, a website that's been years in the making
Janssen Oncology rolls out Cancer.com, a website that's been years in the making
Fierce Pharma
Janssen
cancer
JNJ
digital marketing
Flag link:
ASH 2017: What you missed
ASH 2017: What you missed
BioPharma Dive
ASH17
Biomarin
Spark Therapeutics
Gilead Sciences
Novartis
Juno Therapeutics
AbbVie
Roche
JNJ
Flag link:
[forum discussion]Pfizer Jumps the Shark over Biosimilar Failure
[forum discussion]Pfizer Jumps the Shark over Biosimilar Failure
Cafepharma Message Boards
Pfizer
biosimilars
Inflectra
Remicade
JNJ
Flag link:
ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing risks in half
ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing risks in half
Fierce Pharma
ASH17
JNJ
Darzalex
Multiple Myeloma
Janssen
Flag link:
What To Make Of J&J's First Xarelto Lawsuit Loss
What To Make Of J&J's First Xarelto Lawsuit Loss
Forbes
JNJ
bloodthinners
Xarelto
Flag link:
Pfizer Accuses J&J of Anticompetitive Business Practices over Remicade Biosimilar
Pfizer Accuses J&J of Anticompetitive Business Practices over Remicade Biosimilar
JD Supra
Pfizer
JNJ
Remicade
biosimilars
anticompetitive practices
Celltrion
Flag link:
J&J, Lilly, Merck have best management in pharma, says report
J&J, Lilly, Merck have best management in pharma, says report
BioPharma Dive
JNJ
Eli Lilly
Merck
Management
Wall Street Journal
Flag link:
In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst
In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst
Fierce Pharma
AbbVie
psoriasis
risankizumab
JNJ
Tremfya
Flag link:
J&J, Sanofi ranked best for clinical trial transparency
J&J, Sanofi ranked best for clinical trial transparency
BioPharma Dive
JNJ
Sanofi
clinical trials
transparency
clinical trial data
Flag link:
As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report
As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report
Fierce Pharma
JNJ
biosimilars
Remicade
Europe
anti-TNF
Flag link:

Pages